PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first paragraph were incorrect. The corrected release follows: BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on January 23, 2026, the compensation committee of BridgeBio’s board of directors approved e ...

Company Overview - BridgeBio Pharma, Inc. (NASDAQ:BBIO) focuses on developing therapies for genetic diseases and cancers, with a particular emphasis on precision cancer treatments through its oncology-focused spin-off, BridgeBio Oncology Therapeutics (BBOT) [3]. Financial Performance - For the fourth quarter of 2025, BridgeBio reported preliminary unaudited revenues of $146.0 million, contributing to a total of $362.4 million in product revenue for the full year of 2025 [2]. - The strong revenue figures indicate rapid market adoption of Attruby, which has become a first-choice treatment for newly diagnosed ATTR-CM patients, with over 6,000 unique prescriptions written by the end of 2025 [2]. Analyst Ratings - Truist raised its price target on BridgeBio to $86 from $80 while maintaining a Buy rating, reflecting confidence in the company's future performance [1]. - Analysts remain positive on BridgeBio following the strong results for 2025, indicating a favorable outlook for the company's growth [2].

Core Viewpoint - BridgeBio Pharma, Inc. has announced the pricing of $550 million in 0.75% convertible senior notes due 2033, aimed at raising funds for various corporate purposes, including repurchasing existing convertible notes and shares [1][3][8]. Group 1: Offering Details - The offering consists of $550 million aggregate principal amount of 0.75% convertible senior notes, with an option for initial purchasers to buy an additional $82.5 million [1][2]. - The expected net proceeds from the sale are approximately $538.4 million, or $619.3 million if the option is fully exercised [2]. - The notes will bear interest at a rate of 0.75% per year, payable semi-annually, and will mature on February 1, 2033 [5][8]. Group 2: Use of Proceeds - The net proceeds will be used to repurchase or settle obligations related to the Company's 2.50% convertible senior notes due 2027 and for general corporate purposes [3]. - Approximately $82.5 million of cash on hand will be used to repurchase about 1.1 million shares of common stock from certain purchasers of the notes [4]. Group 3: Conversion and Redemption Terms - The initial conversion rate is set at 9.0435 shares per $1,000 principal amount of notes, equating to an initial conversion price of approximately $110.58 per share, representing a 45% premium over the last reported sale price of $76.26 [6][8]. - The Company may redeem the notes starting February 6, 2030, under certain conditions, at a redemption price equal to 100% of the principal amount plus accrued interest [7][10]. Group 4: Company Overview - BridgeBio Pharma is focused on developing transformative medicines for genetic diseases, with a pipeline that includes early science to advanced clinical trials [13].

Core Viewpoint - BridgeBio Pharma, Inc. plans to offer $550 million in convertible senior notes due 2033 to strengthen its balance sheet, lower interest expenses, reduce dilution, and extend debt maturity [1] Group 1: Offering Details - The offering will be made to qualified institutional buyers under Rule 144A of the Securities Act [1] - The company may grant initial purchasers an option to buy an additional $82.5 million in notes [1] - The final terms of the notes, including interest rate and conversion rate, will be determined at pricing [4] Group 2: Use of Proceeds - Net proceeds from the offering will be used to repurchase or settle obligations related to the company's 2.50% convertible senior notes due 2027 and for general corporate purposes [2] - Up to $82.5 million of cash on hand will be used to repurchase shares of common stock from certain purchasers of the notes [3] Group 3: Notes Characteristics - The notes will bear interest semi-annually and mature on February 1, 2033, with specific conditions for conversion prior to November 1, 2032 [4] - The company may redeem the notes starting February 6, 2030, under certain conditions [5] - The notes will rank senior in right of payment to subordinated unsecured indebtedness and will be structurally junior to all subsidiary liabilities [6] Group 4: Company Overview - BridgeBio Pharma, Inc. focuses on developing transformative medicines for genetic diseases, with a pipeline ranging from early science to advanced clinical trials [9]

Financial Performance - The company reported a net product revenue of $146 million for Q4 2025[7]. - Revenue for the last quarter reached $1.2 billion, representing a 15% increase compared to the previous quarter[18]. - The company has set a future revenue guidance of $1.5 billion for the next quarter, indicating a projected growth of 25%[18]. - Projected peak annual sales of approximately $640 million for the LGM2I/R9 product line[23]. - Projected peak year sales for the new product are expected to exceed $2 billion[33]. - Bridge Bio ended 2025 with $587.5 million in cash, cash equivalents, and marketable securities[93]. Clinical Trials and Research - The company has obtained FDA approval for 3 medicines and is conducting ongoing pivotal trials impacting 8,500 patients[3]. - The company has 15 active trials in its ecosystem, focusing on late-stage and early-stage programs[6]. - The study included 409 participants receiving acoramidis and 202 receiving placebo, highlighting the robust sample size[13]. - The Phase 3 interim analysis for the LGM2I/R9 has shown positive results, with a fully enrolled patient population as of October 2025[24]. - The company is focusing on expanding its market presence with new product developments and strategic approvals[31]. - The company is advancing its research and development efforts, particularly in the area of chronic hypoparathyroidism, with a Phase 3 study initiation planned for Summer 2026[46]. Product Development and Pipeline - The company has engaged in 19 INDs created, indicating a robust pipeline for future product development[3]. - The company is studying the impact of its product across clinical dimensions and has approved a product with a label specifying near-complete stabilization of TTR[12]. - The company is focusing on expanding its product offerings to include new treatment options for children aged 3-18 years[57]. - The company is developing new technologies to improve the predictability of disease mechanisms, which could lead to better treatment options[70]. - The company is committed to ongoing research and development of new products and technologies to meet market demands[34]. Market Expansion and Strategy - The company is expanding its market presence in Asia, targeting a 30% increase in market share by the end of the year[16]. - A strategic acquisition is planned, which is anticipated to enhance the company's technology capabilities and add $200 million in annual revenue[18]. - The company is focusing on expanding its market presence through strategic partnerships and potential acquisitions in the biotech sector[23]. - The company aims to leverage its market research to inform strategic decisions regarding future product launches and market expansions[56]. - The company is exploring new strategies for market expansion and potential acquisitions to enhance its portfolio[64]. Efficacy and Safety - Acoramidis reduced the risk of CVM recurrent CVH by 49% compared to placebo by Month 30[14]. - The company achieved a notable 82% decrease in CK levels at 12 months compared to placebo, indicating strong efficacy[25]. - The treatment has shown a favorable safety profile with no CNS side effects reported during preclinical and phase 1 dosing[80]. - The company reported a clean safety profile with no notable adverse events in treatment groups[88]. - The company achieved significant improvements in animal models for achondroplasia, with femur length increasing by 21%, humerus by 12%, tibia by 33%, ulna by 22%, and radius by 24%[51]. Regulatory and Approval Pathways - The FDA acknowledged the data demonstrating consistent treatment effects on multiple efficacy endpoints, recommending the company to orient the NDA toward traditional approval[31]. - The FDA has provided recommendations for the traditional approval pathway for BBP-418, enhancing the potential for market entry[91]. - The current path to potential BLA filing is expected in 2027 for BBP-812, with rapid uptake in diagnosis of ADH1 involving over 1,700 unique patients identified since October 2023[91]. - The company successfully completed a meeting with the FDA and anticipates filing an NDA in 1H 2026[32]. Patient Impact and Market Opportunity - The projected prevalence for Friedreich's ataxia in the US is estimated to be between 4,000 to 5,000 patients, highlighting a substantial market opportunity[23]. - The current addressable population with ADH1 in the US is estimated to be 12K individuals[34]. - The anticipated increase in diagnosed cases of ADH1 patients is expected to drive future sales growth[33]. - The achondroplasia market includes over 55,000 individuals diagnosed with the condition in the US/EU, representing a potential global market exceeding $5 billion[47]. - The cumulative number of ADH patients diagnosed reached 21,000, with a 17% compound monthly growth rate (CMGR) since the introduction of the ICD-10 code in October 2023[41].

PresentationKicking off the conference, we have BridgeBio. And then presenting on behalf of the company, we have CEO, Neil Kumar. Neil?All right. Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Priyanka Grover, Joyce Zhou and Rati Pinge.Neil KumarCo-Founder, CEO & Director Well, thanks, everyone, for taking the time this morning. I'd like to thank Mike, Ben and the entire JPMorgan t ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Summary of BridgeBio Pharma FY Conference Call Company Overview - **Company**: BridgeBio Pharma (NasdaqGS:BBIO) - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 12, 2026 - **CEO**: Neil Kumar Key Points Company Milestones - BridgeBio celebrates its 10th anniversary, having developed a highly efficient R&D engine for genetic diseases with three approved products and three more expected in the next 12 months [2][3] - Nearly 20 Investigational New Drug (IND) applications generated, impacting approximately 10,000 patient lives [3] Financial Performance - Q4 revenue pre-announced at **$146 million**, representing a **35% growth** from the previous quarter and suggesting a **60% compound annual growth rate (CAGR)** [4] - Total revenue for the first four quarters reached **$362 million** [5] - The company aims for a **30%-35% peak year market share** by volume for its product Attruby, with over **25% market share** achieved in the first year [5] Product Updates ATTR Cardiomyopathy - Attruby is the first and only near-complete stabilizer approved by the FDA, showing a **42% relative risk reduction** in all-cause mortality and cardiovascular hospitalization at 30 months [6] - Over **50 publications** and abstracts have been released regarding the drug's efficacy and patient population performance [6] Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) - Interim phase three results showed a **1.8 times increase** in glycosylation of the alpha-dystroglycan complex and an **82% decrease** in muscle damage [15] - Statistically significant improvements in ambulation and breathing were observed, indicating potential therapeutic cures for some patients [16] ADH1 - Phase 3 results indicated a **76% responder rate** for normalization of urine and serum calcium levels, significantly outperforming the standard of care [20] - The company has identified **1,700 unique patients** with ADH1 through improved genetic testing and updated guidelines [24] Chronic Hypoparathyroidism - A trial showed **80% normalization** of urine and serum calcium levels, with plans to initiate the Reclaim HP trial mid-year [26] Achondroplasia and Hypochondroplasia - The company is advancing its small molecule program targeting FGFR3 over-activation, with phase three data expected in Q1 [28][29] Canavan Disease - A gene therapy approach is being developed, with a BLA filing anticipated in 2027 [36] Market Strategy - The company employs a decentralized model for product launches, leveraging existing infrastructure to minimize costs [37] - Market research indicates a potential **52% market share** for its new products based on favorable profiles compared to existing treatments [34] Future Outlook - BridgeBio emphasizes that it is still "day one" in the era of genetic medicine, with ongoing advancements in genetic research and therapeutic development [38][39] - The company is focused on identifying new patient populations and expanding its pipeline, with **17 early-stage programs** in development at Gondola Bio [40] Conclusion - BridgeBio is well-financed and positioned for significant growth, aiming to serve more patients with innovative therapies in the coming years [48]

Core Insights - BridgeBio Pharma reported preliminary unaudited Q4 and Full Year 2025 net product revenue of $146.0 million and $362.4 million respectively, indicating strong commercial performance for its product Attruby (acoramidis) [1] - Attruby is becoming the preferred therapy for newly diagnosed ATTR-CM patients, with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, driven by its differentiated clinical data and increasing real-world confidence [1] - The company announced a new TTR amyloid depleter antibody program aimed at exploring the potential for ATTR-CM disease reversal, with clinical advancement expected between 2027 and 2028 [1] - Interim analysis from the FORTIFY Phase 3 study of BBP-418 in LGMD2I/R9 showed significant benefits, leading the FDA to recommend a traditional full approval pathway, with an NDA submission planned for the first half of 2026 [1] - A rapid increase in the diagnosis of ADH1 has been noted, with over 1,700 unique patients identified since October 2023, and an NDA submission for encaleret based on CALIBRATE trial results is anticipated in the first half of 2026 [1] - The initiation of the RECLAIM-HP Phase 3 trial for encaleret in chronic hypoparathyroidism is scheduled for summer 2026 following a successful End of Phase 2 interaction with the FDA [1] - The PROPEL 3 Phase 3 study of infigratinib for children with achondroplasia has achieved LPLV, with topline results expected by the end of Q1 2026 [1] - As of December 31, 2025, the company had approximately $587.5 million in cash, cash equivalents, and marketable securities, positioning it well to support the acceleration of Attruby and potentially launch three additional medicines globally [1] Company Overview - BridgeBio Pharma is a biopharmaceutical company focused on genetic diseases, founded in 2015, with a commitment to delivering transformative medicines quickly and effectively [2][7] - The company operates on a decentralized model, aiming to double the number of patients served by the end of 2026 [2]

Commercial Momentum & Patient Impact - Attruby achieved $146 million in Q4 2025 net product revenue[16] - Attruby had 6,629 unique U S patient prescriptions[19] - Attruby's estimated share of NBRx is greater than 25%[19] Clinical & Regulatory Progress - BBP-418 showed a 1 8x increase in glycosylated αDG at 3 months and an 82% decrease in CK at 12 months[46] - BBP-418 treated patients experienced a clinically meaningful 2 6 point benefit on NSAD relative to placebo at 12 months[51] - The FDA recommended orienting the NDA for BBP-418 toward traditional approval[54] - Encaleret achieved a 76% responder rate in the CALIBRATE trial, demonstrating superiority to conventional therapy[60, 62] - Over 1,700 unique patients were diagnosed with ADH in the U S over a 24-month period[67] Pipeline Development - A new antibody depleter program was announced for ATTR-CM[30] - The Phase 3 trial for Infigratinib in achondroplasia achieved Last Patient Last Visit (LPLV)[81] - GondolaBio's PORT-77 in EPP demonstrated approximately 75% reduction in Plasma PPIX at high dose in Phase 2a trial[126] Financial Position - BridgeBio ended 2025 with $587 5 million in cash, cash equivalents, and marketable securities[141]